Pfizer CFO Dave Denton goes Inside the ICE House to discuss how the company is navigating its post‑COVID transition and positioning itself for a return to sustainable growth later this decade. He details Pfizer’s major strategic investments in oncology and metabolic health, including the Seagen and Metsera deals, and explains how proven platforms, global scale, and financial discipline are central to those moves. Denton also shares how execution, patient‑centric innovation, and emerging technologies like AI are shaping the next chapter of Pfizer’s growth story.